Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the present study is to study the effect of baricitinib administration on
outcome of participants with moderate and severe traumatic intracerebral
hemorrhage/contusions. A multi-center randomized control trial will be conducted.
Participants with a radiological diagnosis of traumatic intracerebral hemorrhage/contusions
and an initial GCS score of 5-12 will be screened and enrolled in the first 24 hours after
traumatic brain injury.